Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
CLN-049 by Cullinan Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval
CLN-049 is under clinical development by Cullinan Therapeutics and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...
Data Insights
Risk adjusted net present value: What is the current valuation of Cullinan Therapeutics's CLN-049?
CLN-049 is a monoclonal antibody commercialized by Cullinan Therapeutics, with a leading Phase I program in Myelodysplastic Syndrome. According to...